These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23439259)

  • 1. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.
    Lawitz E; Rodriguez-Torres M; Stoehr A; Gane EJ; Serfaty L; Bhanja S; Barnard RJ; An D; Gress J; Hwang P; Mobashery N
    J Hepatol; 2013 Jul; 59(1):11-7. PubMed ID: 23439259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.
    Zeuzem S; Berg T; Gane E; Ferenci P; Foster GR; Fried MW; Hezode C; Hirschfield GM; Jacobson I; Nikitin I; Pockros PJ; Poordad F; Scott J; Lenz O; Peeters M; Sekar V; De Smedt G; Sinha R; Beumont-Mauviel M
    Gastroenterology; 2014 Feb; 146(2):430-41.e6. PubMed ID: 24184810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.
    Hayashi N; Nakamuta M; Takehara T; Kumada H; Takase A; Howe AY; Ludmerer SW; Mobashery N
    J Gastroenterol; 2016 Apr; 51(4):390-403. PubMed ID: 26403160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
    Ferenci P; Asselah T; Foster GR; Zeuzem S; Sarrazin C; Moreno C; Ouzan D; Maevskaya M; Calinas F; Morano LE; Crespo J; Dufour JF; Bourlière M; Agarwal K; Forton D; Schuchmann M; Zehnter E; Nishiguchi S; Omata M; Kukolj G; Datsenko Y; Garcia M; Scherer J; Quinson AM; Stern JO;
    J Hepatol; 2015 Jun; 62(6):1246-55. PubMed ID: 25559324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.
    Manns MP; Gane E; Rodriguez-Torres M; Stoehr A; Yeh CT; Marcellin P; Wiedmann RT; Hwang PM; Caro L; Barnard RJ; Lee AW;
    Hepatology; 2012 Sep; 56(3):884-93. PubMed ID: 22473713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.
    Tatum H; Thuluvath PJ; Lawitz E; Martorell C; DeMicco M; Cohen S; Rustgi V; Ravendhran N; Ghalib R; Hanson J; Zamparo J; Zhao J; Cooney E; Treitel M; Hughes E
    J Viral Hepat; 2015 Aug; 22(8):658-64. PubMed ID: 25496007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
    Rodriguez-Torres M; Stoehr A; Gane EJ; Serfaty L; Lawitz E; Zhou A; Bourque M; Bhanja S; Strizki J; Barnard RJ; Hwang PM; DiNubile MJ; Mobashery N
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1029-37.e5. PubMed ID: 24120953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
    Rodriguez-Torres M; Lawitz E; Kowdley KV; Nelson DR; Dejesus E; McHutchison JG; Cornpropst MT; Mader M; Albanis E; Jiang D; Hebner CM; Symonds WT; Berrey MM; Lalezari J
    J Hepatol; 2013 Apr; 58(4):663-8. PubMed ID: 23183528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
    Kumada H; Mochida S; Suzuki F; Chayama K; Karino Y; Nakamura K; Fujimoto G; Howe AY; Ludmerer SW; Mobashery N
    J Gastroenterol Hepatol; 2016 Oct; 31(10):1674-1683. PubMed ID: 26936417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study.
    Hayashi N; Mobashery N; Izumi N
    J Gastroenterol; 2015 Feb; 50(2):238-48. PubMed ID: 25115901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.
    Manns MP; Bourlière M; Benhamou Y; Pol S; Bonacini M; Trepo C; Wright D; Berg T; Calleja JL; White PW; Stern JO; Steinmann G; Yong CL; Kukolj G; Scherer J; Boecher WO
    J Hepatol; 2011 Jun; 54(6):1114-22. PubMed ID: 21145839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin.
    Foster GR; Ferenci P; Asselah T; Mantry P; Dufour JF; Bourlière M; Forton D; Maevskaya M; Wright D; Yoshida EM; García-Samaniego J; Oliveira C; Wright M; Warner N; Sha N; Quinson AM; Stern JO
    J Viral Hepat; 2016 Mar; 23(3):227-31. PubMed ID: 26572686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
    J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
    Feld JJ; Jacobson IM; Jensen DM; Foster GR; Pol S; Tam E; Jablkowski M; Berak H; Vierling JM; Yoshida EM; Perez-Gomez HR; Scalori A; Hooper GJ; Tavel JA; Navarro MT; Shahdad S; Kulkarni R; Le Pogam S; Nájera I; Eng S; Lim CY; Shulman NS; Yetzer ES
    J Hepatol; 2015 Feb; 62(2):294-302. PubMed ID: 25239078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
    Sulkowski MS; Asselah T; Lalezari J; Ferenci P; Fainboim H; Leggett B; Bessone F; Mauss S; Heo J; Datsenko Y; Stern JO; Kukolj G; Scherer J; Nehmiz G; Steinmann GG; Böcher WO
    Hepatology; 2013 Jun; 57(6):2143-54. PubMed ID: 23359516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
    Dieterich D; Asselah T; Guyader D; Berg T; Schuchmann M; Mauss S; Ratziu V; Ferenci P; Larrey D; Maieron A; Stern JO; Ozan M; Datsenko Y; Böcher WO; Steinmann G
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3429-36. PubMed ID: 24709256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.
    Larrey D; Lohse AW; de Ledinghen V; Trepo C; Gerlach T; Zarski JP; Tran A; Mathurin P; Thimme R; Arastéh K; Trautwein C; Cerny A; Dikopoulos N; Schuchmann M; Heim MH; Gerken G; Stern JO; Wu K; Abdallah N; Girlich B; Scherer J; Berger F; Marquis M; Kukolj G; Böcher W; Steffgen J
    J Hepatol; 2012 Jul; 57(1):39-46. PubMed ID: 22414766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
    Flamm SL; Lawitz E; Jacobson I; Bourlière M; Hezode C; Vierling JM; Bacon BR; Niederau C; Sherman M; Goteti V; Sings HL; Barnard RO; Howe JA; Pedicone LD; Burroughs MH; Brass CA; Albrecht JK; Poordad F
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.